On June 23, 2021, Vita Therapeutics, Inc. closed the transaction. The company amended the terms of the transaction. The company will now issue $32 million in a round of funding. The company has raised $12 million in its second trance. The transaction was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures. The round was oversubscribed. The company received $11,999,992 pursuant to regulation D in the transaction from 15 investors.